[{"orgOrder":0,"company":"Rezo Therapeutics","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rezo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rezo Therapeutics \/ SR One Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Rezo Therapeutics \/ SR One Capital Management"}]
Find Oncology Clinical Drug Pipeline Developments & Deals by Rezo Therapeutics
Details :
Rezo aims to rapidly advance a pipeline of therapies, initially focused in solid tumor oncology guided by mutation and allele-specific biomarkers.
Reset All
